FGF9 and metabolic dysfunction-associated steatohepatitis: FGF9 induces non‐alcoholic steatohepatitis (NASH) to develop into severe fibrosis and eventually lead to hepatocellular carcinoma (HCC) by promoting extracellular matrix (ECM) accumulation.